Assertio Holdings, Inc.
Assertio Holdings, Inc. (ASRT): 64 pipeline candidates · 1 upcoming catalyst · ~15 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.8 months
D/E 1.79 · 0% dilution
Lead: Approved
64 candidates
1 upcoming, next in ~2311d
N/A
A transparent, data-derived signal for Assertio Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$151.9M
Cash
$33.7M
Quarterly Burn
$19.9M
Runway
14.8 mo
Revenue
$9.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (64 candidates)
| Drug | Phase |
|---|---|
| 6-Mercaptopurine | Phase 2 |
| Acetaminophen | Phase 2 |
| Asparaginase Erwinia chrysanthemi | Phase 3 |
| Blinatumomab | Phase 3 |
| Busulfan | Phase 2 |
| Cabozantinib S-malate | Phase 2 |
| Calaspargase | Phase 2 |
| Calaspargase Pegol | Phase 3 |
| CAMBIA | Approved |
| Cemiplimab | Phase 2 |
Showing 10 of 64 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
64
Total value held
$37.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 537,904 | $10.3M |
| renaissance technologies llc | 228,599 | $4.4M |
| susquehanna international group, llp | 181,600 | $3.5M |
| edgewood management llc | 107,517 | $2.0M |
| blackrock, inc. | 90,035 | $1.7M |
| jane street group, llc | 79,436 | $1.5M |
| geode capital management, llc | 76,314 | $1.5M |
| citadel advisors llc | 74,562 | $1.4M |
| sei investments co | 54,940 | $1.0M |
| huntleigh advisors, inc. | 52,603 | $1.0M |
Showing top 10 of 64 institutional holders of Assertio Holdings, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Assertio Holdings, Inc.'s pipeline?
Assertio Holdings, Inc. (ASRT) has 64 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Assertio Holdings, Inc.'s lead drug candidate?
Assertio Holdings, Inc.'s most advanced tracked candidate is 6-Mercaptopurine (Phase 2) for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative.
What is Assertio Holdings, Inc.'s next catalyst?
Assertio Holdings, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VYXEOS" — expected October 15, 2032.
What is Assertio Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Assertio Holdings, Inc. has approximately 14.8 months of cash runway.
What is Assertio Holdings, Inc.'s market capitalization?
Assertio Holdings, Inc.'s market capitalization is approximately $151.9M.
Get the full picture on Assertio Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.